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Abstract
Objective This study was designed to examine the mutual
relationship between 8-isoprostane in exhaled breath con-
densate (EBC) and superoxide anion generation by
bronchoalveolar lavage ﬂuid (BALF) cells in patients with
sarcoidosis.
Design About 29 patients with sarcoidosis, 34 healthy
never smokers (control group for EBC) and 15 healthy
never smokers (control group for BAL) were examined.
EBC was collected directly before bronchoscopy. 8-Iso-
prostane was measured by ELISA, and superoxide anion by
colorimetry.
Results Exhaled breath condensate 8-isoprostane is
increased in sarcoidosis (median, 25–75 percentile): 2.50;
2.50–3.90 versus 6.20; 2.50–16.95 pg/ml, p B 0.05).
Spontaneous superoxide anion release from BALF cells
was signiﬁcantly elevated only in patients with a high
percentage of lymphocytes in BALF (6.42 ± 1.24 vs.
23.52 ± 4.30 nmol/10
6 cells, p B 0.01). There were no
correlations between 8-isoprostane and spontaneous or
stimulated superoxide anion release.
Conclusions We conﬁrmed higher concentrations of EBC
8-isoprostane in sarcoidosis and higher spontaneous release
of superoxide anion from BALF cells in patients with sar-
coidosis. The increase of EBC 8-isoprostane is not directly
related to superoxide anion released from BALF cells.
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Introduction
Oxidative stress has been implicated in the pathophysiol-
ogy of many lung diseases. An example is idiopathic
pulmonary ﬁbrosis (IPF), a disease characterized by fatal
prognosis due to massive lung ﬁbrosis and unresponsive-
ness to treatment [1]. Increased ex-vivo production of
superoxide anion or hydrogen peroxide by cells from
bronchoalveolar lavage (BAL) have also been reported in
sarcoidosis [2, 3], but secondary markers of oxidative
stress, such as oxidized proteins, or oxidized methionine
residues in BAL ﬂuid (BALF) are not increased in
sarcoidosis, contrary to IPF [4–6].
Exhaled breath condensate is a relatively new, promis-
ing and non-invasive method that enables collecting
biological material from lower respiratory tract in order to
measure various biomarkers [7]. 8-Isoprostane is a marker
of oxidative stress. It is a prostaglandin-F2a isomer, pro-
duced in vivo by free radical-catalyzed peroxidation of
arachidonic acid [7–9]. Elevated concentrations of 8-iso-
prostane in BALF [10] and exhaled breath condensate
(EBC) [11, 12] in patients with sarcoidosis have been
reported. However, the clinical value of this ﬁnding is still
unknown. There is some hope that this biomarker could be
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Reactive oxygen species (ROS) activate metalloproteinases
and inactivate their inhibitors [13, 14], or stimulate cells to
release TGF-b and other pro-ﬁbrogenic cytokines [15].
Also, alveolar epithelial cells apoptosis can be induced by
ROS [16]. All these mechanisms may be involved in the
pathogenesis of chronic and progressive lung sarcoidosis.
We have previously reported increased 8-isoprostane in
exhaled breath condensate in patients with sarcoidosis [12].
Further, we found that spontaneous, rather than PMA-stim-
ulated, superoxide anion production by BAL cells is
increasedinsarcoidosis[17].Thepresent studywas planned
to evaluate the correlation between both spontaneous and
PMA stimulated superoxide anion generation and EBC
8-isoprostane.
Materials and methods
Study and control groups
Twenty-nine patients with newly diagnosed, histo-patho-
logically conﬁrmed sarcoidosis were included. All were
non-smokers, non-atopic and had never been treated with
steroids or immunosuppressive drugs. There were no other
co-morbidities. Respiratory infection in the last 4 weeks
was an exclusion criterion. Based on the radiological
classiﬁcation, there were 9 patients with stage I, 14 with
stage II, and 6 with stage III. The control group for EBC
8-isoprostane consisted of 34 healthy never-smokers,
members of the hospital staff and medical students. The
control group for superoxide release from BALF cells con-
sisted of 15 healthy non-smokers who had undergone
bronchoscopy due to unspeciﬁc clinical/radiological signs,
ﬁnally proved not to be related to any lung pathology.
Characteristics ofthe study and control groups are presented
in Table 1.
Bronchoscopy was performed with a ﬂexible broncho-
scope (Pentax
, Japan) according to British Thoracic
Society Guidelines [18]. Patients optionally received
midanium and atropine before the examination, 2% lido-
caine was used as a topical anaesthetic.
Bronchoalveolar lavage ﬂuid (BALF) was collected
from medial lobe or lingula by instillation and subsequent
withdrawal of 4 9 50 ml of 0.9% NaCl. The ﬂuid recovery
was 57 ± 2%. The crude BALF was ﬁltered through
gauze, centrifuged, and the pellet was suspended in a
phosphate buffer. The total cell count (TCC) was presented
as n 9 10
6. Cytospin slides were prepared and stained by
May-Gru ¨nwald-Giemsa stain. Numbers of macrophages,
lymphocytes, neutrophils and eosinophils were calculated
under a light microscope and presented as percent of TCC.
Moreover, total cells and particular cell types were pre-
sented as number of cells (n 9 10
4) per ml of recovered
ﬂuid.
Superoxide anion (O2
-) production by BALF cells was
measured colorimetrically, as previously described [19].
The method is based on the reduction of cytochrome C by
superoxide anion. Superoxide dismutase was used to inhi-
bit the reaction. Spontaneous and excess release after
stimulation with PMA (1 ng/ml, for 20 min) were mea-
sured. Values were expressed as nmol O2
-/10
6 cells.
Due to the fact that lymphocytes could be neglected as
a source of oxidants, we presented these values as nmol
O2
-/10
6 cells potentially producing superoxide anion
(macrophages, neutrophils, eosinophils). This value was
calculated according to the following formula: C =
n x 100/100-y, where n is the production of superoxide
by all BALF cells, and y is a percentage of BALF
lymphocytes.
Collection of exhaled breath condensate
The exhaled breath condensate (EBC) was collected using
a condensing device (Ecoscreen, Jaeger, Germany).
Patients were asked to breathe out spontaneously for 10
min through a mouthpiece equipped with a saliva trap. The
respiratory rate ranged from 15 to 20 breaths/min. All
Table 1 Characteristics of the control and study groups
Control EBC Control BAL Sarcoidosis all Sarcoidosis stage I Sarcoidosis stage II Sarcoidosis stage III
Gender (females/males) 20/14 7/8 13/16 5/4 6/8 2/4
Age (years) 39.8 ± 2.6 43.6 ± 4.0 40.2 ± 2.0 39.4 ± 2.8 38.6 ± 2.8 45.3 ± 6.0
FEV1% predicted 104.2 ± 2.7 103.3 ± 3.1 92.9 ± 3.0 97.4 ± 4.1 86.7 ± 3.4 102.0 ± 10.1
FVC % predicted 108.6 ± 3.2 103.0 ± 3.1 94.8 ± 3.1 97.6 ± 5.5 91.9 ± 3.0 98.0 ± 11.7
FEV1/FVC % 81.2 ± 1.1 84.4 ± 1.6 84.9 ± 1.5 89.0 ± 2.2 81.5 ± 1.9 87.2 ± 3.3
DLCOc % predicted – – 83.2 ± 3.6 91.1 ± 5.1 79.7 ± 4.6 73.4 ± 13.8
BAL lymphocytes % – 9.5 ± 1.1 34.7 ± 4.4 39.3 ± 8.0 31.6 ± 5.8 35.0 ± 12.4
BAL bronchoalveolar lavage; DLCO diffusion capacity for carbon monoxide corrected for hemoglobin concentration; EBC exhaled breath
condensate; FEV1 forced expiratory volume in ﬁrst second of expiration; FVC forced vital capacity
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distilled water just before and in the seventh minute of the
condensing process in order to reduce nasal contamination.
Samples were stored at -80C for not longer than 4 weeks
until measurements were taken. The collection of EBC was
performed following available recommendations [20],
always before the bronchoscopy.
8-Isoprostane concentrations in breath condensate were
measured by a speciﬁc enzyme immonoassay (EIA) kit
(Cayman Chemical, Ann Arbor, MI), as previously
described [12]. The detection limit was 5 pg/ml. Levels of
measured mediators below the detection limit were arbi-
trarily assumed to be half of the detection limit value.
8-Isoprostane was also measured in BAL, and results were
used for estimation of correlations. BAL 8-isoprostane
results for the control group are not available.
Statistical analysis
Data were expressed as mean ± standard error of means
(SEM). The Kolmogorow-Smirnoff test was used to assess
normality. Median with 25th and 75th percentiles was
provided for non-normally distributed data. Unpaired
T-test (for normally distributed data) and Mann–Whitney
test (for non-parametric data) were used to compare
sarcoidosis with the controls. When more than two groups
were compared, one-way ANOVA and Bonferroni post-test
(for data with Gaussian distribution) or Kruskall-Wallis
followed by Dunn’s Multiple Comparison Test (for data
without normal distribution) were used. The Spearman test
was applied to assess correlations. A p value B0.05 was
deemed statistically signiﬁcant.
The study was approved by Ethical Committee at
Medical University of Lodz (consent No. RNN/99/08/KE)
and all patients signed informed consent.
The funding source had no inﬂuence on the study.
Results
Concentrations of 8-isoprostane in EBC were higher in
sarcoidosis (median; 25–75 percentile: 2.50; 2.50–3.90 vs.
6.20; 2.50–16.95 pg/ml, p\0.05). Although there were no
signiﬁcant differences between radiological stages, the
signiﬁcance was highest when stage III was compared with
controls (26.35; 3.90–33.85 pg/ml, p\0.01, Fig. 1) and
between controls and patients with low lymphocyte per-
centage in BALF (15.10; 5.10–34.50 pg/ml, p\0.01,
Fig. 2a).
Superoxide anion release, both spontaneous (mean ±
SEM: 6.42 ± 1.24 vs. 17.08 ± 2.87 nmol/10
6 cells) and
PMA-stimulated excess superoxide release (median; 25–75
percentile: 1.74; 0–6.01 vs. 5.90; 0–28.01 nmol/10
6 cells),
in all sarcoidosis patients showed no signiﬁcant difference
compared to controls in this study. Neither in the case of
spontaneous nor that of PMA-stimulated release were there
any signiﬁcant differences between patients with different
radiological stages. Patients with high lymphocyte
Fig. 1 Comparison of 8-isoprostane concentration in exhaled breath
condensate (EBC) of controls (C), all sarcoidosis patients (S) and
patients divided according to radiological stages (SI, SII and SIII)
Fig. 2 EBC 8-isoprostane (a) and spontaneous superoxide anion
release from BAL cells (b) depending on high and low lymphocyte
percentage in BAL ﬂuid versus controls. The bars are limited by 25th
and 75th percentiles, lines within bars represent means, T-bars
represent maxima. C controls; S sarcoidosis; L BAL lymphocytes B15
or C25%. Other abbreviations: BAL bronchoalveolar lavage; EBC
exhaled breath condensate; ns not signiﬁcant
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tions of spontaneous superoxide anion compared to
controls (mean ± SEM: 23.52 ± 4.30 nmol/10
6 cells,
p\0.01, Fig. 2b).
We did not ﬁnd any correlations between EBC 8-iso-
prostane and spontaneous (r =- 0.06; p = 0.76) or
PMA-stimulated superoxide anion release (r =- 0.10;
p = 0.61). BAL 8-isoprostane was correlated with EBC
results (r = 0.64, p = 0.0004), but was not correlated with
spontaneous (r = 0.10, p = 0.63) or stimulated superoxide
release (r = 0.02, p = 0.92).
Exhaled breath condensate 8-isoprostane concentrations
were negatively correlated with the percentage of lym-
phocytes in BALF (r =- 0.40; p = 0.03).
PMA-stimulated superoxide production was positively
correlated with the number of neutrophils in BALF
(r = 0.48; p = 0.009).
Bronchoalveolar lavage 8-isoprostane correlated nega-
tively with FVC percent predicted (r =- 0.41, p = 0.049)
and FEV1/FVC ratio (r =- 0.49, p = 0.02).
Discussion
Although elevated concentrations of 8-isoprostanes in EBC
[11, 12] and increased release of superoxide anion from
alveolar cells after stimulation [2] in patients with sar-
coidosis have already been reported, this is the ﬁrst study
on the mutual relationship between EBC 8-isoprostane and
both PMA stimulated and spontaneous production of
superoxide by BAL cells.
Despite the evident radiological and functional pro-
gression, several markers of activity are used in everyday
practice, starting from various laboratory markers in serum
or BAL, through increased Ga
67 uptake in scintigraphy
scans, to changes in BALF cellular pattern. None of these
markers is speciﬁc nor sensitive enough; in addition none
adds much to the ability to determine future prognosis and
indications to treatment. One of the best markers of
activity, elevated percentage of lymphocytes in BALF
(with high CD4/CD8 ratio), reﬂects only the intensity of
lymphocytic alveolitis. Highly elevated content of lym-
phocytes is a typical feature of those with acute onset and
evidently better prognosis [21, 22]. Other changes in BALF
cellular pattern, however, may have some negative prog-
nostic value. For instance, high content of neutrophils and
eosinophils were reported in those with chronic course and
increased risk of lung ﬁbrosis [22, 23]. It may be important
that these cells are very potent producers of reactive oxy-
gen species (ROS) and other toxic substances, which may
be released upon stimulation of NADPH-oxidase, or other
ROS-generating intracellular sources. Our ﬁnding of higher
spontaneous release of superoxide anion from BALF cells
of patients with active lymphocytic inﬂammation suggests
that BALF macrophages are constantly stimulated in vivo,
and so release superoxide anion spontaneously. Other
authors also conﬁrm such a possibility, showing sponta-
neous release of gamma-interferon from alveolar
macrophages and lung T lymphocytes in sarcoidosis [24].
This type of ROS production seems to be related to the
intensity of lymphocytic inﬂammation, and evidently is not
a feature of a more severe disease. In clinical practice,
however, the most problematic patients are those with low
activity markers, low lymphocyte content in BALF, but
with progression of lung changes.
Exhaled breath condensate 8-isoprostane, although
increased in sarcoidosis, is not only unrelated to the pro-
duction of superoxide anion by BALF cells, but seems to
show reverse trends in relation to percentage of lympho-
cytes. The highest levels have been found in patients with
radiological stage III. In our previous study [12], we found
that increased EBC 8-isoprostane in sarcoid patients was
not correlated with BALF lymphocytes, but were corre-
lated with BALF eosinophils, and BALF eosinophils were
inversely correlated with DLCO. The present study, dedi-
cated to the mutual relationship between the momentary
production of superoxide anion by activated BALF cells
and 8-isoprostane in EBC, seems to conﬁrm our earlier
observations. These results are also consistent with the
results of Montuschi et al. [10], who found that BAL
8-isoprostane in sarcoidosis negatively correlates with
BAL lymphocytes.
We provided BAL 8-isoprostane results, but only for the
estimation of correlations. We did not ﬁnd any between
BAL 8-isoprostane and superoxide production by BAL
cells. We conﬁrmed our earlier ﬁndings of a positive cor-
relation between EBC and BAL 8-isoprostane [12].
Moreover, weak but negative correlations between BAL
8-isoprostane and FVC percent predicted and FEV1/FVC
ratio conﬁrm our main results.
The lack of BAL 8-isoprostane results for the control
group is an important limitation of the present study. The
main reason was the lack of consent from the healthy
volunteers (EBC control group) to be subjected to bron-
choscopy. On the other hand, the control group for BAL,
although consisting of healthy subjects, is not an ‘‘ideal’’
control group for EBC. As the primary objective of the
study was the estimation of the correlations between
exhaled breath 8-isoprostane and superoxide generation,
we decided to approve this disadvantage.
One of the limitations of the use of 8-isoprostane in the
monitoring of sarcoidosis and other lung diseases is a wide
range of results in a study group and a substantial over-
lapping with control group results. One of the factors that
could be responsible for this ﬁnding may be different
antioxidant potential of individual subjects, which may be
1030 W. J. Piotrowski et al.genetically determined [25]. 8-Isoprostane is not a speciﬁc
marker for sarcoidosis, therefore other inﬂammatory
diseasesmayinﬂuencetheresults.Certainly,boththecontrol
and study groups were strictly selected towards exclusion
criteria, such as infection, atopy and other inﬂammatory
diseases of the respiratory and digestive tracts, but some
subclinical states cannot be excluded with 100% certainty.
The two most likely explanations of the discrepancy
between EBC 8-isoprostane and superoxide production by
BAL cells are the following:
First, that superoxide anion and other ROS may be
scavenged immediately after formation by naturally
occurring antioxidants, preventing further peroxidation of
membrane phospholipids. Although antioxidant protection
was not analyzed in this paper, this possibility should be
tested in a separate study.
Second , that other than alveolar inﬂammatory cells,
sources of ROS may play a role in initiation of lipid
peroxidation. For instance, alveolar epithelial cells covering
a huge area of alveoli are potent sources of reactive oxygen
and nitrogen species [26, 27].
The overall conclusion is that 8-isoprostane and super-
oxide generation by BAL cells characterize different
processes. The latter is related to the intensity of inﬂam-
mation, and is more common in less severe forms.
8-Isoprostane, related to peroxidation of lipid membranes,
may describe chronic destruction linked to more chronic
forms and worse prognosis. The latter statement deserves
further follow-up studies for conﬁrmation of the prognostic
value of EBC 8-isoprostane.
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